



Study	I^2			Odds Ratio (95% Crl)
Erlotinib_antiangio vs Erlotinib				
15				7.0 (2.1, 23.)
16				5.6 (2.9, 11.)
18		<	\rightarrow	6.1e+09 (8.2e-06, 4.5e+24)
2				13. (5.4, 30.)
24			\longrightarrow	57. (4.9, 6.7e+02)
25				2.4 (0.36, 16.)
34				4.3 (1.3, 14.)
35 36				3.8e+11 (6.6e-07, 2.2e+29)
37				2.7 (1.0, 7.1) 7.4e+10 (3.4e-18, 1.6e+39)
41				7.9 (3.1, 20.)
Pooled (pair-wise)	30.1%			7.2 (4.0, 16.)
Indirect (back-calculated)	301170			NA
Pooled (network)	30.4%			7.3 (3.5, 21.)
Placebo vs Erlotinib				
46		←	\longrightarrow	1.6e+14 (1.1e-08, 2.2e+36)
Pooled (pair-wise)				3.2e+15 (9.6, 4.7e+56)
Indirect (back-calculated)				3.4 (0.13, 93.)
Pooled (network)	31.3%			3.8 (0.16, 1.2e+02)
antiangio vs Erlotinib				
28			── →	16. (3.2, 82.)
37				1.6e+12 (1.0e-06, 2.7e+30)
Pooled (pair-wise)	28.7%			16. (2.0, 2.3e+02)
Indirect (back-calculated)				2.3e+03 (36., 1.4e+05)
Pooled (network)	69.5%		\longrightarrow	55. (9.5, 5.9e+02)
		0.03	1 30)



